ABSTRACT

Introduction: Progress in the diagnostic-therapeutic approach in lung cancer has been achieved thanks to the knowledge of tumor heterogeneity and optimization in molecular analysis. Material and methods: Cases of patients with lung cancer from 2015 to 2018 were reviewed, recording sociodemographic, clinical, molecular and result variables of T790M. The results were expressed in measures of central tendency and Kaplan-Meier curves were constructed. Results: Of the total of patients with lung cancer in INER, it was found that 93.74% (n = 704) were non-small cell lung cancer, 86% (n = 606) were adenocarcinomas and 42.63% (n = 191) had sensitive mutated EGFR. A total of 30 samples were sent to T790M determination, being positive at 50%. The majority were female, never smokers. The median progression-free survival was 13 months. Conclusion: In this study we found a resistance frequency acquired in T790M higher than in other countries. These allow to know the importance of the determination of T790M in patients who receive inhibitors of tyrosine kinase in front of the progression offering a second line in time of impact on the prognosis.

KEYWORDS

Lung cancer, TKI, T790M.

REFERENCES

1. Globocan 2018. Population Fact Sheets, “Mexico”. Consultado en: http://gco.iarc.fr/today/data/factsheets/populations/484-mexico-factsheets. pdf

2. Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol 2016;40(12):e94-e102. doi: 10.1097/PAS.0000000000000749.

3. Aldaco-Sarvide F, Pérez-Pérez P, Cervantes-Sánchez G, Torrecillas- Torres L, Erazo-V AE. Mortalidad por cáncer en México 2000–2010: El recuento de los daños. GAMO 2012;11(6):371-379.

4. Ruiz-Godoy L, Rizo RP, Sánchez CF, Osornio-Vargas A, García- Cuellar C, Meneses GA. Mortality due to lung cancer in Mexico. Lung Cancer 2007;58(2):184-190. doi: 10.1016/j.lungcan.2007.06.007.

5. Iniesta SP. Carcinogénesis pulmonar. Rev Patol Respir 2007;10(1):50-54.

6. Gómez RC, de Castro CJ, González BM. Factores etiológicos del cáncer de pulmón: fumador activo, fumador pasivo, carcinógenos medioambientales y factores genéticos. Med Clin 2007;128(10):390- 396. https://doi.org/10.1157/13099973

7. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321(7257):323-329. doi: 10.1136/bmj.321.7257.323.

8. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54(1):12-27. doi: 10.1111/j.1365- 2559.2008.03176.x.

9. Spiro SG, Gould MK, Colice GL; American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory test, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):149S-160S. doi: 10.1378/chest.07-1358.

10. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.

11. Arrieta O, Guzmán de Alba E, Alba-López F, Acosta-Espiniza A, Alatorre-Alexander J, Alexander-Meza JF, et al. Consenso Nacional de Diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin 2013;65(Supl1):s5-s84.

12. Franco-Marina F, Villalba CJ. La epidemia de cáncer pulmonar en México. Rev Inst Nal Enf Resp Mex 2001;14(4):207-214.

13. Ruano-Ravina A, Pérez RM, Fernández-Villar A. Cribado de cáncer de pulmón con tomografía computarizada de baja dosis después del National Lung Screening Trial. El debate continúa abierto. Arch Bronconeumol 2013;49(4):158-165. doi: 10.1016/j.arbres.2012.10.003.

14. Yotsukura M, Yasuda H, Shigenobu T, Kaseda K, Masai K, Hayashi Y, et al. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. Lung Cancer 2017;109:45-51. doi: 10.1016/j.lungcan.2017.04.014.

15. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315(3):971-979. doi: 10.1124/ jpet.105.084145.

16. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008;20(2):162-175. doi: 10.1097/ CCO.0b013e3282f335a3.

17. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-2139. doi: 10.1056/NEJMoa040938.

18. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010;9:75. doi: 10.1186/1476-4598-9-75.

19. Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12(24):7222- 7231. doi: 10.1158/1078-0432.CCR-06-0627.

20. Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, et al. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer 2016;16(1):864. doi: 10.1186/s12885-016-2902-0.

21. Koo H, Kim MY, Park S, Lee HN, Kim HJ, Lee DH, et al. Non-small cell lung cancer with resistance to EGFR-TKI therapy: CT characteristics of T790M mutation-positive cancer. Radiology 2018;289(1):227-237. doi: 10.1148/radiol.2018180070.

22. Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, et al. The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Cancer Res Treat 2018;50(4):1294-1303. doi: 10.4143/crt.2017.512.